Project Grant R01AI203734
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $842K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waltham, MA 02453, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $1,032,783 to Massachusetts General Hospital on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on broadly neutralizing antibodies against HIV. The research, led by Dr. Alejandro Balazs at the Ragon Institute of MGH, MIT & Harvard, focuses on engineering the immune system through gene...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $251,875 on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the structural basis of antibody-mediated Fc-effector functions in HIV-1 immune complexes. The research establishes a cryo-electron microscopy platform to directly observe how antibodies bound to HIV-1 envelope glycoproteins on virions are recognized by Fc gamma receptors on plasma membrane blebs and...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $888,042 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate N332-glycan-independent V3-glycan antibodies as targets for HIV-1 vaccine design. The research develops novel broadly neutralizing antibody responses against HIV-1 envelope protein by studying vaccine candidates that elicit antibodies binding to the V3-glycan epitope...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a Project Grant totaling $1,486,296 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the human antibody response to Cryptococcus neoformans and survival outcomes in HIV-associated cryptococcal meningoencephalitis, a devastating opportunistic infection of the central nervous system that occurs predominantly in people...
- The National Institute of Allergy and Infectious Diseases awarded Rush University Medical Center $269,500 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess the role of HIV-specific IgA glycosylation on transport and function as a foundation for anti-HIV IgA immunotherapy. The research will characterize glycosylation patterns of bulk IgA isolated from people living with HIV and compare them to non-HIV controls, assessing how these glycosylation...